Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives


 19th June 2012 Encap Drug Delivery

D3 Pharma and Encap Drug Delivery continue partnership

Livingston, United Kingdom, June 18th 2012

D3 Pharma Limited today announces its continuing partnership with Encap Drug Delivery to expedite the commercial manufacturing and product licensing programme for its proprietary high-dose oral vitamin D3 product, PlenacholTM, for the treatment of vitamin D deficiency and insufficiency.

PlenacholTM is a patented liquid-filled capsule formulation of vitamin D3 which was developed in conjunction with Encap and is available at three dose-strengths: 20,000, 40,000 and 100,000 international units. PlenacholTM has a unique formulation base which is free from animal derived excipients and peanut constituents. The utility of Encap’s world-class capsule liquid-filling technology secures PlenacholTM as a first and best-in-class high-dose oral vitamin D3 product.

PlenacholTM will continue to be made available as a Specials product during the pre-license phase via Encap Drug Delivery. For more information regarding PlenacholTM Specials supply please contact: Dr Janice McLachlan (

About D3 Pharma

D3 Pharma is a privately owned specialty pharmaceutical company based in the United Kingdom. It is committed to the research, development and commercialisation of licensed high-dose vitamin D3 medicinal products for the treatment of vitamin D deficiency, insufficiency and associated conditions. D3 Pharma’s pioneering work in the vitamin D deficiency area aims to address a significant unmet need and improve vitamin D product access world-wide.

About Encap Drug Delivery

Encap Drug Delivery is the world’s largest contract development and manufacturing organization (CDMO) totally dedicated to liquid and semi-solid (hot melt) filled capsules. The company was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing and high volume commercial manufacturing. Encap’s state-of-the-art facility in the UK has been audited by the FDA and MHRA and supplies clinical and commercial products to all major global markets including EU, North and South America and Japan.

For further information please contact: For further information please contact Dr Hiep Huatan, D3 Pharma Ltd (+44 1622 630057) or Dr Stephen Brown, Encap Drug Delivery (+44 1506 448080).


Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |